ЛИТЕРАТУРА
1. DeLellis R.A., Osamura R.Y. Neuroendocrine tumors: an overview // Pathol. Case Rev. 2006. Vol. 11. P. 229-234.
2. el-Naggar A.K., Troncoso P., Ordonez N.G. Primary renal carcinoid tumor with molecular abnormality characteristic of conventional renal neoplasms // Diagn. Mol. Pathol. 1995. Vol. 4. P. 48-53.
3. Cao D., Selli B.W., Clapp W.L. et al. Primary renal carcinoid tumors: clinicopathologic features of 9 cases with emphasis on novel immunohistochemical findings // Hum. Pathol. 2011. Vol. 42, N 10. P. 1554-1561.
4. La Rosa S., Bernasconi B., Micello D. et al. Primary small cell neuroendocrine carcinoma of the kidney: morphological, immunohistochemical, ultrastructural, and cytogenetic study of a case and review of the literature // Endocr. Pathol. 2009. Vol. 20, N 1. P. 24-34.
5. Romero F.R., Rais-Bahrami S., Permpongkosol S. et al. Primary carcinoid tumors of the kidney // J. Urol. 2006. Vol. 176. P. 2359-2366.
6. Lane B.R., Jour G., Zhou M. Renal neuroendocrine tumors // Indian J. Urol. 2009. Vol.25, N 2. P. 155-160.
7. Dundr P., Pešl M., Povýšil C. et al. Primary large cell neuroendocrine carcinoma of the kidney // Pathol. Oncol. Res. 2010. Vol. 16, N 1. P. 139-142.
8. Aung P.P., Killian K., Poropatich C.O. et al. Primary neuroendocrine tumors of the kidney: morphological and molecular alterations of an uncommon malignancy // Hum. Pathol. 2013. Vol. 44, N 5. P. 873-880. DOI: https://doi.org/10.1016/j.humpath.2012.08.013
9. Hannah J., Lippe B., Lai-Goldman M. et al. Oncocytic carcinoid of the kidney associated with periodic Cushing’s syndrome // Cancer. 1988. Vol. 61. P. 2136-2140.
10. Hamilton I., Reis L., Bilimoria S. et al. A renal vipoma // Br. Med. J. 1980. Vol. 281. P. 1323-1324.
11. Gleeson M.H., Bloom S.R., Polak J.M. et al. Endocrine tumour in the kidney affecting small bowel structure, motility and absorptive function // Gut. 1971. Vol. 12. P. 773-782.
12. Kawajiri H., Onoda N., Ohira M. et al. Carcinoid tumor of the kidney presenting as a large abdominal mass: report of a case // Surg. Today. 2004. Vol. 34. P. 86-89.
13. Eichhorn J.H., Young R.H. Neuroendocrine tumors of the genital tract // Am. J. Clin. Pathol. 2001. Vol. 115, suppl. 1. P. 94-112.
14. Mazzucchelli R., Morichetti D., Lopez-Beltran A. et al. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance // BJU Int. 2009. Vol. 103, N 11. P. 1464-1470.
15. Finci R., Gunham O., Celasun B. et al. Carcinoid tumor of undescended testis // J. Urol. 1987. Vol. 137. P. 301-302.
16. Stroosma O.B., Delarere K.P. Carcinoid tumours of the testis // BJU Int. 2008. Vol. 101, N 9. P. 1101-1105.
17. Zavala-Pompa A., Ro J.Y., el-Naggar A. et al. Primary carcinoid tumor of testis. Immunohistochemical, ultrastructural, and DNA flow cytometric study of three cases with a review of the literature // Cancer. 1993. Vol. 72. P. 1726-1732.
18. Talerman A., Gratama S., Miranda S. et al. Primary carcinoid tumor of the testis: case report, ultrastructure and review of the literature // Cancer. 1978. Vol. 42. P. 2696-2706.
19. Zavala-Pompa A., Ro J.Y., El-Naggar A. et al. Primary carcinoid tumor of the testis: immunohistochemical, ultrastructural, and DNA flow cytometric study of three cases with a review of the literature // Cancer. 1993. Vol. 72. P. 1726-1732.
20. Kato N., Motoyama T., Kameda N. et al. Primary carcinoid tumor of the testis: Immunohistochemical, ultrastructural and FISH analysis with review of the literature // Pathol. Int. 2003. Vol. 53. P. 680-685.
21. Merino J., Zuluaga A., Gutierrez-Tejero F. et al. Pure testicular carcinoid associated with intratubular germ cell neoplasia // J. Clin. Pathol. 2005. Vol. 58. P. 1331-1333.
22. Haupt H.M., Mann R.B., Trump D.L. et al. Metastatic carcinoma involving the testis: clinical and pathologic distinction from primary testicular neoplasms // Cancer. 1984. Vol. 54. P. 709-714.
23. Balzer B.L., Ulbright T.M. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases // Am. J. Surg. Pathol. 2006. Vol. 30. P. 858-865.
24. Merino J., Zuluaga A., Gutierrez-Tejero F. et al. Pure testicular carcinoid associated with intratubular germ cell neoplasia // J. Clin. Pathol. 2005. Vol. 58. P. 1331-1333.
25. Ulbright T.M., Young R.H. Carcinoid tumor of the testis // Am. J. Clin. Pathol. 2004. Vol. 121. P. 297-298.
26. Abbosh P. H., Zhang S., MacLennan G.T. et al. Germ cell origin of testicular carcinoid tumors // Clin. Cancer. Res. 2008. Vol. 14. P. 1393-1396.
27. Verdorfer I., Horst D., Hollrigl A. et al. Leydig cell tumors of the testis: a molecularcytogenetic study based on a large series of patients // Oncol. Rep. 2007. Vol. 17. P. 585-589.
28. Reyes A., Moran C.A., Suster S. et al. Neuroendocrine carcinomas (carcinoid tumor) of the testis. A clinicopathologic and immunohistochemical study of ten cases // Am. J. Clin. Pathol. 2003. Vol. 120, N 2. P. 182-187.
29. Kwekkeboom D.J., Krenning E.P. Somatostatin receptor scintigraphy in patients with carcinoid tumors // World J. Surg. 1996. Vol. 20, N 2. P. 157-161.
30. Sutherland R.S., Wettlaufer J.N., Miller G.J. Primary carcinoid tumor of the testicle: a case report and management schema // J. Urol. 1992. Vol. 148. P. 880-882.
31. Sasaki M., Emura M., Kim U. et al. Primary carcinoid tumor of the testis metastatic to the paraaortic lymph nodes in six years after the first operation: a case report // Hinyokika Kiyo. 2009. Vol. 55, N 4. P. 233-236.
32. Zuetenhorst J.M., Taal B.G. Metastatic carcinoid tumors: a clinical review // Oncologist. 2005. Vol. 10. P. 123-131.
33. Bostwick D.G., Grignon D.J., Hammond M.E. et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999 // Arch. Pathol. Lab. Med. 2000. Vol. 124, N 7. P. 995-1000.
34. Isaacs J.T. Prostate stem cells and benign prostatic hyperplasia // Prostate. 2008. Vol. 68, N 9. P. 1025-1034.
35. Bonkhoff H., Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model // Prostate. 1996. Vol. 28, N 2. P. 98-106.
36. Lesser B., Brukhovsky N. Effect of duration of the period after castration on the response of the rat ventral prostate to androgens // Biochem. J. 1974. Vol. 142, N 2. P. 429-431.
37. Evans G.S., Chandler J.A. Cell proliferation studies in the rat prostate: II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation // Prostate. 1987. Vol. 11, N 4. P. 339-351.
38. Kurita T., Medina R.T., Mills A.A. et al. Role of p63 and basal cells in the prostate // Development. 2004. Vol. 131, N 20. P. 4955-4964.
39. Leong K.G., Wang B.E., Johnson L. et al. Generation of a prostate from a single adult stem cell // Nature. 2008. Vol. 456, N 7223. P. 804-808.
40. Collins A.T., Habib F.K., Maitland N.J. et al. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression // J. Cell Sci. 2001. Vol. 114. pt 21. P. 3865-3872.
41. Richardson G.D., Robson C.N., Lang S.H. CD133, a novel marker for human prostatic epithelial stem cells // J. Cell Sci. 2004. Vol. 117, pt 16. P. 3539-3545.
42. Litvinov I.V., Vander Griend D.J., Xu Y. et al. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells // Cancer Res. 2006. Vol. 66, N 17. P. 8598-8607.
43. Vander Griend D.J., Karthaus W.L., Dalrymple S. et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells // Cancer Res. 2008. Vol. 68, N 23. P. 9703-9711.
44. Sotomayor P., Godoy A., Smith G.J. et al. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells // Prostate. 2009. Vol. 69, N 4. P. 401-410.
45. Aumuller G., Leonhardt M., Jansenn M. et al. Neurogenic origin of human prostate endocrine cells // Urology. 1999. Vol. 53, N 5. P. 1041-1048.
46. Di Sant’agnese P.A., De Mesy Jensen K.L. Endocrine-paracrine cells of the prostate and prostatic urethra: an ultrastructural study // Hum. Pathol. 1984. Vol. 15, N 11. P. 1034-1041.
47. Vashchenko N., Abrahamson P.A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities // Eur. Urol. 2005. Vol. 47, N 2. P. 147-155.
48. Krijnen J.L., Jansenn P.J., Ruizeweld de Winter J.A. et al. Do neuroendocrine cells in human prostate cancer express androgen receptor? // Histochemistry. 1993. Vol. 100, N 5. P. 393-398.
49. Yang J.C., Or J.H., Busby J.E. et al. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer // Cancer Res. 2009. Vol. 69, N 1. P. 151-160.
50. Yuan T.C., Veeramani S., Lin M.F., Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells // Endocr. Relat. Cancer. 2007. Vol. 14, N 3. P. 531-547.
51. Schalken J.A., Van Leenders G., Cellular and molecular biology of the prostate: stem cell biology // Urology. 2003. Vol. 62, N 5. Suppl. 1. P. 11-20.
52. Huang J., Yao J.L., Di Sant’agnese P.A. et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer // Prostate. 2006. Vol. 66, N 13. P. 1399-1406.
53. Xue Y., Verhovstad A., Lange W. et al. Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate // Am. J. Pathol. 1997. Vol. 151, N 6. P. 1759-1765.
54. Kasper S., Stem cells: The root of prostate cancer? // J. Cell. Physiol. 2008. Vol. 216, N 2. P. 332-336.
55. Hurt E.M., Kawasaki B.T., Klarmann G.J. et al. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis // Br. J. Cancer. 2008. Vol. 98, N 4. P. 756-765.
56. Vander Griend D.J., Karthaus W.L., Dalrymple S. et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells // Cancer Res. 2008. Vol. 68, N 23. P. 9703-9711.
57. Lawson D.A., Xin L., Lukacs R.U. et al. Isolation and functional characterization of murine prostate stem cells // Proc. Natl Acad. Sci. USA. 2007. Vol. 104, N 1. P. 181-186.
58. Palapattu G.S., Wu C., Silvers C.R. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer // Prostate. 2009. Vol. 69, N 7. P. 787-798.
59. Sotomayor P., Godoy A., Smith G.J. et al. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells // Prostate. 2009. Vol. 69, N 4. P. 401-410.
60. Duran I., Berthold D. R., Pond G. R. et al. Neuroendocrine carcinoma of the prostate: review of 14 cases at a single institution from 1988-2004 // 2007 Prostate Cancer Symposium. General Poster Session B. Abstr. 253.
61. Komiya A., Suzuki H., Imamoto T. et al. Neuroendocrine differentiation in the progression of prostate cancer // Int. J. Urol. 2009. Vol. 16, N 1. P. 37-44.
62. Weinstein M.H., Partin A.W., Veltri R.W. et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy // Hum. Pathol. 1996. Vol. 27, N 7. P. 683-687.
63. Theodorescu D., Broder S.R., Boyd J.C. et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate // Cancer. 1997. Vol. 80, N 11. P. 2109-2119.
64. May M., Siegsmund M., Hammeraman F. et al. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy // Scand. J. Urol. Nephrol. 2007. Vol. 41, N 5. P. 375-381.
65. Mcwilliam L.J., Manson C., George N.J. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma // Br. J. Urol. 1997. Vol. 80, N 2. P. 287-290.
66. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer // Clin. Cancer Res. 2006. Vol. 12, N 6. P. 1665-1671.
67. Harris W.P., Mostaghel E.A., Nelson P.S. et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion // Nat. Clin. Pract. Urol. 2009. Vol. 6, N 2. P. 76-85.
68. Taplin M.E. Drug insight: role of the androgen receptor in the development and progression of prostate cancer // Nat. Clin. Pract. Oncol. 2007. Vol. 4, N 4. P. 236-244.
69. Sasaki T., Komiya A., Suzuki H. et al. Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients // Eur. Urol. 2005. Vol. 48, N 2. P. 224-229.
70. Sciarra A., Di silverio F. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma // Urology. 2004. Vol. 63, N 3. P. 523-527.
71. Tarle M., Ahel M.Z., Kovacic K. Acquired neuroendocrinepositivity during maximal androgen blockade in prostate cancer patients // Anticancer Res. 2002. Vol. 22, N 4. P. 2525-2529.
72. Himisha B., David S., Kyung P. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets // Cancer Discov. 2011. Vol. 1. P. 487-495.